Drug Discovery Weekly — November 6, 2026
This week features a historic FDA approval for a functional cure for chronic Hepatitis B and a major transparency crackdown on clinical trial sponsors. Key developments include Vera Therapeutics' submission for TRUTAKNA in IgA nephropathy, CG Oncology's upcoming bladder cancer data readouts, and a significant surge in global biopharma dealmaking driven by Chinese licensing partnerships.
Drug Discovery Weekly — November 6, 2026
FDA & Regulatory Decisions
Hepatitis B Drug (Company Unspecified in Source) — Approval
- Indication: Chronic Hepatitis B (CHB)
- Significance: This approval marks the first drug offering a "functional cure" for CHB, a condition responsible for over one million deaths worldwide annually. It represents a pivotal shift from viral suppression to potential cure.
- Timeline: Approved this week; immediate availability expected.
TRUTAKNA (Vera Therapeutics) — sBLA Submission
- Indication: Primary IgA Nephropathy (IgAN) in adults
- Significance: Vera Therapeutics completed its supplemental Biologics License Application (sBLA) for full approval. This follows the final efficacy analysis of the ORIGIN 3 trial, which is set for simultaneous publication in The New England Journal of Medicine at Week 2026.
- Timeline: sBLA submitted; full approval decision pending FDA review.
Clinical Trial Transparency Enforcement (FDA) — Regulatory Action
- Indication: General Clinical Trials
- Significance: In a move to enforce long-standing rules, the FDA has warned approximately 2,200 clinical trial sponsors for failing to report missing results. This signals a new era of stricter oversight regarding data transparency.
- Timeline: Warnings issued late October/early November 2026.
Clinical Trial Milestones
Cretostimula greniblja (CG Oncology) — Phase 3 for Bladder Cancer
- Sponsor: CG Oncology
- Results: The company reports that 12-month data from two ongoing trials are expected in December. The company maintains cash runway through 2029 to support these operations.
- What's Next: Completion of the BLA submission for BCG-unresponsive bladder cancer is targeted for Q4 2026.
RAS-Addicted Cancer Candidates (Revolution Medicines) — Pipeline Update
- Sponsor: Revolution Medicines
- Results: The company reported third-quarter financial results and provided updates on corporate progress for its portfolio targeting RAS-addicted cancers, a historically difficult-to-drug target class.
- What's Next: Continued development of innovative medicines for RAS-mutant tumors.
Oncology Fast Track Designations — Various Sponsors
- Sponsor: Multiple
- Results: The FDA granted fast track designations to several drugs during October 2026, covering indications in lung, prostate, and gastrointestinal cancers.
- What's Next: Accelerated review timelines for these newly designated candidates.
Pharma Deals & M&A
-
Licensing Deal: AbbVie + Brise Pharmaceuticals — Up to $757 million. AbbVie licensed two experimental migraine drugs from Beijing-based Brise Pharmaceuticals, highlighting the trend of Western pharma sourcing innovation from China.
-
Strategic Acquisition/Licensing: Novartis + Abogen — $7.8 billion. Novartis signed a massive licensing deal with Chinese biotech Abogen. This transaction underscores the growing importance of Chinese biotech platforms as Western companies face looming patent cliffs.
- October Dealmaking Overview: The most expensive biotech M&A in October 2026 was valued at $2 billion, with licensing deals spanning various therapeutic technologies. Global dealmaking was characterized by high-value licensing agreements and platform collaborations in oncology, particularly involving ADCs and T-cell engagers.
AI & Computational Drug Discovery
-
Industry Status: Despite advances in protein structure prediction and generative molecular design, industry trackers report that no AI-discovered drug had won full approval by October 2026. The primary bottleneck remains clinical attrition rather than discovery capability.
-
Pipeline Integration: Companies such as Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, and XtalPi continue to advance AI-enabled candidates into clinical stages. However, the translation of AI-predicted compounds into clinically successful therapeutics remains a critical challenge for the sector.
Pipeline Watch: Key Upcoming Catalysts
- December 2026: CG Oncology to release 12-month data from two trials regarding cretostimula greniblja.
- Q4 2026: CG Oncology expects to complete BLA submission for BCG-unresponsive bladder cancer.
- Week 2026: Final efficacy analysis of Vera Therapeutics' ORIGIN 3 trial to be published in NEJM.
Week in Context
The past week highlights a bifurcation in drug development: while regulatory bodies are cracking down on historical transparency failures with mass warnings to trial sponsors, the industry is simultaneously accelerating toward high-stakes approvals in areas previously deemed "undruggable" or difficult to cure, such as Chronic Hepatitis B. The approval of a functional cure for CHB stands out as a potentially paradigm-shifting event for hepatology, offering hope to millions of patients globally.
Furthermore, the economic landscape of biopharma is increasingly defined by cross-border innovation sourcing. The $7.8 billion Novartis-Abogen deal and AbbVie’s licensing of migraine drugs from China illustrate a strategic pivot where Western pharma giants are actively acquiring or licensing assets from Chinese biotechs to replenish pipelines ahead of patent cliffs. This trend is reshaping the competitive landscape, making China a central hub for early-stage oncology and immunology innovation, particularly in modalities like ADCs and mRNA-based therapies.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
